LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker Reveals Cause of Papillary Thyroid Carcinoma

By LabMedica International staff writers
Posted on 26 Oct 2014
Image: Tumor cell populations identified using digital image analysis from a stained pathology slide, with the tumor regions detected and now colored orange (Photo courtesy of Definiens).
Image: Tumor cell populations identified using digital image analysis from a stained pathology slide, with the tumor regions detected and now colored orange (Photo courtesy of Definiens).
The expression of the CAP-GLY domain containing linker protein 2 (CLIP2) provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin.

The biomarker CLIP2 serves as a radiation marker because after exposure to radiation from radioiodine, both the genetic activity and the protein expression are increased especially among children exposed to the radioiodine fallout and have developed papillary thyroid carcinoma (PTC).

Scientists at the Helmholtz Zentrum München (Neuherberg, Germany), and their international colleagues, studied PTCs from a cohort of young patients exposed to the post-Chernobyl radioiodine fallout at very young age and a matched non-exposed control group. They investigated the potential role of CLIP2 as a radiation marker to be used for the individual classification of PTCs into CLIP2-positive and -negative cases, a prerequisite for the integration of CLIP2 into epidemiological modelling of the risk of radiation-induced PTC. A discovery cohort of 33 individuals and two independent validation cohorts of 115 PTCs were investigated.

The team were able to validate the radiation-associated CLIP2 overexpression at the protein level by immunohistochemistry (IHC) followed by relative quantification using digital image analysis software (Definiens AG; Munich, Germany). They analyzed the function of CLIP2 in radiation-associated PTC, by reconstructing the CLIP2 gene regulatory network using global messenger ribonucleic acid (mRNA) expression data from PTC patient samples. The genes comprising the first neighborhood of CLIP2, BCL2-associated athanogene 2 (BAG2), carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3), kinesin family member 3C (KIF3C), neuralized E3 ubiquitin protein ligase 1 (NEURL1), peptidylprolyl isomerase (cyclophilin)-like 3 (PPIL3), and regulator of G-protein signaling 4 (RGS4) suggest the involvement of CLIP2 in the fundamental carcinogenic processes including apoptosis, mitogen-activated protein kinase signaling and genomic instability.

Julia Hess, MD, the senior author of the study said, “CLIP2 serves as a radiation marker and allows us to distinguish between radiation-induced and sporadic thyroid carcinomas. This biomarker allows us both to draw conclusions about the mechanisms involved in the development of such tumors and to evaluate the risk of thyroid cancer after exposure to high level radiation, for instance, following a radiation accident.” The study was published on October 6, 2014, in the journal Oncogene.

Related Links:

Helmholtz Zentrum München 
Definiens AG

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more